YC-1: Soluble Guanylyl Cyclase Activator for Hypoxia and Cancer Research

Introduction & Principle: Harnessing YC-1 in Modern Cancer and Hypoxia Pathway Research

YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline, DMSO-soluble small molecule developed as a dual-function soluble guanylyl cyclase activator and HIF-1α inhibitor. As a research compound, it is central to the study of the hypoxia signaling pathway, oxygen-sensing pathway, and cGMP signaling in both cancer biology and vascular research. YC-1’s mechanism of action is twofold: post-transcriptional inhibition of hypoxia-inducible factor 1α (HIF-1α), a master regulator of hypoxia-adaptive gene expression, and direct activation of soluble guanylyl cyclase (sGC), resulting in reduced platelet aggregation and vascular contraction. This makes YC-1 a versatile tool for probing tumor angiogenesis inhibition, apoptosis, tumor growth inhibition, and circulatory system disorder models. APExBIO supplies YC-1 with >98% purity, ensuring robust, reproducible outcomes for advanced scientific research (YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol).

Step-by-Step Experimental Workflow Enhancements with YC-1

1. Compound Preparation & Solubility Optimization

• YC-1 exhibits excellent solubility in DMSO (≥30.4 mg/mL) and ethanol (≥16.2 mg/mL), but is insoluble in water. For optimal results, prepare concentrated stock solutions in DMSO and dilute into cell culture media or assay buffers immediately prior to use. Avoid long-term storage of diluted solutions to maintain compound integrity.
• Filter sterilize stock solutions through a 0.22 μm syringe filter to eliminate particulates before cell-based or in vivo assays.

2. Model System Selection

• YC-1 is validated in a range of cancer research models, including hepatoma cell lines (e.g., HepG2, Huh7), breast, prostate, and glioblastoma cells. It is also utilized in in vivo tumor xenograft and angiogenesis models.
• For vascular biology studies, YC-1 is applied to investigate platelet aggregation inhibition, vascular contraction modulation, and cGMP signaling in ex vivo vessel rings or primary endothelial cells.

3. Hypoxia Simulation and YC-1 Treatment

• To model tumor microenvironment hypoxia, use hypoxia chambers (1–2% O₂) or chemical inducers (e.g., CoCl₂) for 12–48 hours.
• Treat cells with YC-1 at concentrations ranging from 1–50 μM, optimizing dose and exposure time for your system based on pilot viability and efficacy assays.
• For in vivo studies, YC-1 is typically administered by intraperitoneal injection at doses of 1–10 mg/kg/day, as reported in multiple studies for effective reduction of HIF-1α and tumor vascularization.

4. Experimental Readouts

• HIF-1α and Downstream Gene Expression: Quantify transcript and protein levels of HIF-1α and its target genes (e.g., VEGF, GLUT1, BNIP3) using qPCR and Western blotting.
• Cell Viability and Cytotoxicity: Use MTT, CellTiter-Glo, or flow cytometric apoptosis assays to assess YC-1-induced cancer cell death and proliferation inhibition under hypoxic vs. normoxic conditions.
• Angiogenesis and Migration Assays: Conduct tube formation (Matrigel), scratch assays, or transwell migration/invasion assays in endothelial or cancer cell lines.
• In Vivo Tumor Analysis: Measure tumor volume, vascularization (CD31 immunostaining), and apoptosis (cleaved caspase-3 staining) in xenograft models.

5. Data Analysis & Quantification

• Use standardized normalization controls for gene/protein expression and replicate experiments for statistical robustness.
• Leverage image analysis software for quantifying angiogenesis endpoints and immunohistochemical markers.

Advanced Applications and Comparative Advantages of YC-1

YC-1’s unique dual action as an anticancer drug targeting hypoxia-inducible factor 1 and a circulation disorder research compound offers distinct advantages:

• Hypoxia and Tumor Microenvironment Research: YC-1 efficiently blocks hypoxia-induced gene expression, inhibits tumor angiogenesis, and reduces metastasis, as extensively demonstrated in hepatoma, breast, and glioma models (YC-1: Advanced Insights into HIF-1α Inhibition & Mitochon…). Its impact is most pronounced in hypoxic tumor cores, where HIF-1 signaling drives survival and neovascularization.
• Vascular Biology and Platelet Function: As a potent platelet aggregation inhibitor and vascular contraction inhibitor, YC-1 enables researchers to dissect cGMP-mediated vasoregulation and platelet signaling pathways relevant to thrombosis and circulation disorders.
• Integration with Neuroprotective and Apoptosis Pathways: While the reference study (Molecular Neurobiology, 2024) highlights the neuroprotective effects of calcium channel blockers, YC-1 complements such mechanistic studies by providing direct modulation of the HIF-1α/BNIP3L axis, which intersects with apoptosis regulators like caspase-3. This synergy advances our understanding of cell fate decisions under hypoxia and metabolic stress.
• Workflow Compatibility and Reproducibility: Researchers report over 90% reproducibility in cell-based hypoxia models when using APExBIO’s YC-1, thanks to its high purity and validated solubility profile (Optimizing Cell-Based Assays with YC-1).

Compared to alternative HIF-1α inhibitors, YC-1’s post-transcriptional mechanism yields faster suppression of HIF-1 transcriptional activity, and its sGC activation provides a unique window into NO/cGMP axis research (YC-1: A Soluble Guanylyl Cyclase Activator and HIF-1α Inh…).

Troubleshooting and Optimization Tips: Maximizing YC-1 Performance

• Compound Precipitation: If YC-1 precipitates upon dilution, ensure DMSO concentration is maintained above 0.1% in working solutions and mix thoroughly. Prepare fresh aliquots before each experiment to prevent degradation.
• Cell Line Sensitivity: Some cell types exhibit variable sensitivity to YC-1, particularly under extreme hypoxia. Conduct initial dose-response assays in your model system to fine-tune the effective range and avoid cytotoxicity unrelated to HIF-1 inhibition.
• Assay Timing: YC-1 acts rapidly on HIF-1α protein turnover; shorter treatment windows (4–8 hours) can reveal early transcriptional effects, while 24–48 hours highlight downstream phenotypes (e.g., apoptosis, reduced angiogenesis).
• Assay Controls: Always include normoxic and vehicle-only controls. For pathway specificity, consider co-treatment with sGC inhibitors or HIF-1α stabilizers to dissect YC-1’s dual mechanisms (YC-1: Mechanistic Insights and Novel Therapeutic Horizons…).
• Storage and Stability: Store YC-1 powder at room temperature and protect from moisture. Avoid repeated freeze-thaw cycles of stock solutions. For extended studies, aliquot stocks to minimize degradation.
• Batch Verification: Confirm compound identity and purity via HPLC or mass spectrometry, especially when comparing results across different lots or suppliers. APExBIO provides lot-specific certificates of analysis for traceability.

Future Outlook: YC-1 as a Platform for Translational and Systems Biology Research

Looking ahead, YC-1’s integration into multi-omics workflows and advanced in vivo models will further illuminate the interplay between the hypoxia signaling pathway, tumor angiogenesis, and systemic vascular responses. Recent studies suggest that YC-1, by modulating the HIF-1α/BNIP3L pathway, may have applications in neuroprotection and mitochondrial quality control, extending its utility beyond oncology (Translating Hypoxia Pathway Insights: Strategic Advances…).

Moreover, the combination of YC-1 with epigenetic modulators, kinase inhibitors, or immunotherapy agents holds promise for next-generation cancer and hypoxia-related disease therapies. The compound’s robust performance across diverse cell and animal models, validated by peer-reviewed and supplier-generated data, ensures that it will remain a cornerstone for the next wave of apoptosis and cancer biology research, vascular biology, and circulation disorder investigations.

For detailed product data, protocols, and technical support, visit the official YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol page by APExBIO, the trusted supplier for high-purity research chemicals.